In Brazil, thalidomide has been used virtually without interruption since it was launched as a new and revolutionary sedative drug in 1956. After 1965, when its effi cacy to treat erythema nodosum leprosum (ENL) was discovered, it was regarded as an essential drug because the prevalence of Hansen's disease is high in the country. In the 1990s and thereafter myriad novel therapeutic uses for thalidomide (autoimmmune diseases, multiple myeloma, aphthous ulcers in AIDS, and others) have emerged owing to its immunomodulatory and antiangiogenic activities. Owing to a marked teratogenicity, however, the prescription and dispensing of thalidomide to patients is strictly controlled in Brazil and elsewhere. Notwithstanding the stringent regulations, a number of post-1965 cases of thalidomide embryopathy have occurred in Brazil. In 2003, a federal law (Law 10.651/2003) prohibited the sale and dispensing of thalidomide in commercial pharmacies.
Introduction
Thalidomide holds a unique position in the Brazilian drug regulatory framework. It is the only medicine that is regulated by a specifi c federal law (Law 10.651, 16 April, 2003) 1 . The law forbids the sale and/or dispensing of thalidomide in commercial pharmacies. It also states that thalidomide shall be distributed to public health units/hospitals and dispensed to patients through programs approved by the federal health authority (Ministry of Health) 1 . A copy of a physician's written order (on a special numbered prescription order form) must be retained by the public health unit or hospital pharmacy and sent to the local sanitary surveillance offi ce. The Ministry of Health programs through which thalidomide can be distributed and dispensed are those for Hansen's disease, sexually transmitted diseases and AIDS (i.e., aphthous ulcers in AIDS patients) and chronic degenerative diseases (i.e., for lupus erythematosus and graft-versushost disease) 1, 2 . In addition, the law states that package labeling must warn that thalidomide is strictly prohibited for pregnant women and for women at risk of becoming pregnant. The package inserts must also provide detailed information about the drug and its proven teratogenic effects, and include a responsibility term that must be signed by prescribers and patients. To receive thalidomide, patients must present two documents at the public health unit or hospital pharmacy: a special prescription order and a signed responsibility term. Moreover, federal health programs must provide full information on the teratogenic risks of thalidomide, offer advice on pregnancy prevention methods, and give contraceptives to women of childbearing age under treatment for hanseniasis or any other disease for which the drug is indicated and prescribed 1 
Thalidomide uses, misuses and current regulatory status
Thalidomide was developed by a German pharmaceutical company (Chemie Grünenthal GmbH, founded in 1946) and entered the market as a new and revolutionary sedative drug in the mid-1950s 5, 6, 7, 8, 9 . Compared to the sleeping pills and tranquilizing drugs available until then (e.g., barbiturates and bromides), thalidomide seemed to be safe. Chemie Grünenthal toxicologists claimed that they "could not fi nd a dose high enough to kill a rat", and most physicians believed that suicide attempts with overdoses of thalidomide, unlike those with barbiturates, would be doomed to failure 5, 6, 7, 8, 9 . Although a peripheral neuropathy was noted in patients treated with thalidomide, the manufacturer denied any causal relationship between the drug and this neurological condition and continued to claim that its product was safe 7 . In November 1961, however, Widukind Lenz, a pediatrician and medical geneticist, reported that an ongoing outbreak of birth defects (phocomelia, a pre-axial reduction of limbs, and amelia, or absence of limbs), seldom recorded before the mid-1950s, was due to thalidomide use during pregnancy 5, 6 . The link between intake of thalidomide during gestation (fi rst trimester) and congenital anomalies -noted by Lenz in Germany -was subsequently confi rmed by McBride in Australia 10 and Smithells in the UK 11 . Within a few weeks of these fi rst reports, thalidomide was withdrawn from the market in Germany and Great Britain. In Brazil, Belgium, Canada, Italy, Japan and a few other countries thalidomide continued to be sold for several months thereafter 5, 6, 8, 9 . A suspicion about the neurological side-effects (peripheral neuropathy) delayed the approval of thalidomide in the USA, so that it had not been approved for marketing when the drug-induced epidemic of birth defects came to light. Thanks to Dr Frances Kelsey, a stubborn FDA offi cial, the biggest pharmaceutical market in the world was spared a thalidomide disaster. Although not being sold in pharmacies, thalidomide caused a few cases of congenital anomalies in the USA due to the pre-approval distribution of free drug samples to physicians, a promotional practice intended to "seed the market" 5,6,7,8,9 . Babies with a thalidomide embryopathy phenotype that were born 9 or more months after the drug was banned in Germany and the UK were considered by Lenz as "avoidable cases", many of which were from Brazil and Japan 5, 6, 7, 8, 9 . Thalidomide was banned worldwide in the mid-1960s, but its use was never completely discontinued in Brazil owing to an unex- anti-TNF) and antiangiogenic properties of thalidomide 16 . Between the late 1970s and early 2000, a series of clinical studies showed that thalidomide induced symptomatic remission of aphthous stomatitis 17, 18, 19, 20 , Behçet's disease i 21,22 and prurigo nodularis 23, 24 , and was benefi cial in the treatment of graft-versus-host disease after transplantation 25 , autoimmune diseases such as cutaneous and systemic lupus erythematosus 26, 27, 28 , and certain conditions associated with HIV infection, such as aphthous ulcers and wasting syndrome 29, 30, 31 . A landmark in the emergence of thalidomide as a potentially useful drug in the treatment of some types of cancer ii was the demonstration that it possessed antiangiogenic activity.
A study by Robert D'Amato and coworkers, published in 1994, revealed that thalidomide was an inhibitor of angiogenesis in a rabbit cornea assay 32 . Solid tumors depend on the proliferation of new blood vessels to increase in size, and thus the malignant tissue produces substances that promote its vascularization 33 . Consequently, inhibition of angiogenesis was regarded as a promising pharmacological target for developing an entirely new class of effective anticancer agents iii 33 . Along this line, the next step was to test thalidomide in patients with relapsed and/or refractory multiple myeloma (MM) iv 34 .
In an apparent reaction to an uncontrolled use of thalido- however, the mothers denied any use of thalidomide 42, 43 . As far as this author is aware, the most recent case of thalidomide embryopathy occurred in the state of Maranhão in 2010 vi 44 . A patient with ENL, who had taken thalidomide during gestation, gave birth to a female baby with bilateral upper and lower limb reduction defects 44 . In 2011, a new regulation controlling the dispensing and prescription of thalidomide (introducing a more effective control on drug dispensing for off-label indications) was issued and put into effect by ANVISA, the health regulatory agency of Brazil 45 (Table 1, Figure 2 ). i Behçet's disease or syndrome is a rare immune-mediated small-vessel systemic vasculitis, the symptoms of which include painful oral aphthous ulcers, genital ulcerations, cutaneous pustular lesions and uveitis. ii As several antineoplastic drugs used in the mid-1960s were also teratogenic agents, some clinical researchers speculated that thalidomide, a potent human teratogen, might also possess antitumor properties. Still in the 1960s, thalidomide was trialed in patients with different types of cancer, but investigators found little or no evidence of an effective therapeutic response 35, 36 .
iii In 1971, Judah Folkman highlighted that solid tumors required neovascularization (angiogenesis) for growth and survival 33 . Since then, inhibition of new blood vessel growth has become a potential target for an effective anticancer therapy. Today, several drugs that inhibit angiogenesis are used in oncology to treat different types of tumors. Binding of signaling molecules (e.g., vascular endothelial growth factor, VEGF) to the surface of endothelial cells is required for angiogenesis. Inhibition of angiogenesis can be achieved by using monoclonal antibodies (e.g., bevacizumab) that specifi cally recognize and bind to VEGF, or by other drugs (e.g., sorafenib and sunitinib) that block receptors on the surface of endothelial cells (or other proteins in the downstream signaling pathways) 37, 38 . iv Multiple myeloma, also known as plasma cell myeloma, is an abnormal (malignant) proliferation of plasma cells that can affect the bones, the immune system, the kidneys and the red blood cell count. v The incidence of Hansen's disease is very low in the USA. In 2007, 109 cases of Hansen's disease (most of which were imported) were reported to CDC-USA, whereas 249,009 cases occurred worldwide. Of all cases reported to the WHO in 2008, 77% were from Brazil, India and Indonesia 40 . The rarity of ENL in the USA explains why the FDA had no interest in approving thalidomide. FDA approval came three decades after Sheskin had reported that the drug was effective in treating type II reaction symptoms. vi This case of birth defects -compatible with thalidomide use -was reported to the Ministry of Health (Department of Epidemiological Surveillance/ Hanseniasis Control Program, and the National Agency of Health Surveillance -ANVISA).
Innovative and "me too" drugs
A "me-too" drug vii is a drug that uses essentially the same therapeutic mechanism of action as an existing one, offering no signifi cant additional benefi t in terms of effi cacy and/or safety (i.e., they are not clinically superior). Many "me-too" drugs are chemically related to the prototype and hence are also structurally very similar to one or more drugs already on the market, with only minor differences 46, 47 . In fact, "metoo" drugs largely duplicate the therapeutic action of drugs that are already available. As the R&D of pharmaceuticals is a lengthy process, a "me-too" drug may result from a parallel drug development (i.e., despite being approved for marketing later, a "me-too" drug might have entered development long before the innovative drug began to be used in clinical practice). Nonetheless, in a number of cases "me-too" drugs are intentionally developed imitations of innovative medicines.
The R&D process of a "me-too" drug is more predictable (or less risky) than that of an innovative medicine. At any rate, imitations are developed to compete with the pioneer drug and other existing medicines.
The deliberate development of "me-too" drugs has been questioned because these drugs do not bring additional benefi ts to patients 46, 48 . Focusing on a market for "me-too"s, pharmaceutical companies use funds and resources that could otherwise be applied to the development of innovative medicines, many of which are desperately needed for a number of morbid conditions, including the neglected diseases. Along this line, Marcia Angell 48 and others proposed that a requisite for new drug approval by national regulatory agencies should be evidence not only of effi cacy compared with placebo, but also of clinical superiority (effi cacy and/or safety) to existing therapies. Such a proposal is controversial, and some authors have defended "me-too" drugs, arguing that non-innovative vii "Me-too" drugs are sometimes also called "follow-on" drugs. 
1998
The US FDA approved thalidomide use in ENL.
1999
A clinical trial by Singhal et al. showed that thalidomide is active against advanced multiple myeloma.
2003
Brazil federal law forbade thalidomide sales and dispensing in commercial pharmacies and stated that it should be distributed and dispensed only through Ministry of health programs. A strict control on thalidomide prescription and dispensing is established.
2005
The US FDA fi rst approved lenalidomide (Revlimid™) for myelodysplastic syndrome with deletion of 5q chromosomal abnormality. Despite the federal law, and strict control on the dispensing of thalidomide established by lower level regulation, new cases of babies born with thalidomide embryopathy continued in Brazil (2005-2010).
2006
The US FDA approved thalidomide use in relapsed and/or refractory MM. The US FDA (June 29) approved lenalidomide for use in combination with dexamethasone in patients with MM.
2010
The Brazilian health regulatory agency (ANVISA) denied approval for lenalidomide use in MM and myelodysplastic syndrome.
2011
New rules on thalidomide control, including those regarding the dispensing of thalidomide for off-label indications, were put into effect by ANVISA.
2012
After evaluating a request for reconsideration fi led by the pharmaceutical company, ANVISA confi rmed its previous decision (denial of approval) regarding lenalidomide registration.
2013
The US FDA approved pomalidomide (Pomalyst™) for relapsed and/or refractory MM. medicines enhance competition and stimulate the lowering of prices, which is ultimately benefi cial to consumers.
One diffi culty in imposing restrictions for launching a putative "me-too" on the market is that eventual differences between a structurally related drug and its prototype may appear only after they have been in large-scale use for some time. Another key problem with putative "me-too" drugs is that pharmaceutical companies, in an attempt to boost sales, do not adequately inform physicians and consumers about the degree of similarity of their products to existing drugs. On the contrary, companies generally claim that their ("me-too") products are in some way "better" than pioneer drugs, even when this statement is not supported by adequately designed and conducted comparative effi cacy studies. Along this line, Angell 48 pointed out that many structurally related ("me-too") drugs are never tested at equivalent doses to show that there are signifi cant differences in clinical outcomes for some patients. Thus, in most cases, companies' claims that "patients respond differently to 'me-too' drugs is merely an untested -and self-serving -hypothesis" 48 .
Comparative effi cacy and safety of thalidomide analogues versus thalidomide
A key problem regarding the safety of any thalidomide analogue is to fi nd out whether it, too, has teratogenic properties. This question is not easily answered by routine preclinical studies because rodents are known to be refractory to thalidomide-induced teratogenicity, and rabbits -albeit more susceptible than rats -do not exhibit the same pattern of severe malformations as those found in primates 54, 55, 56 .
A comparative developmental toxicity study of thalidomide and lenalidomide in rabbits showed that the former caused fetal structural anomalies (limb defects and others) in the absence of overt maternal toxicity, whereas the latter did not increase the incidence of malformations and produced other embryotoxic effects (prenatal growth retardation and embryo deaths) only at maternally toxic doses. These results were initially misinterpreted as an indication that lenalidomide would be less teratogenic than thalidomide. Moreover, authors stated in their conclusions that developmental toxicity studies on lenalidomide versus thalidomide would confi rm that "… structure-activity relationships may not predict maternal or developmental effects" 54 . A further non-human primate study, however, revealed that lenalidomide given orally to monkeys Although several clinical studies showed that lenalidomide (e.g., lenalidomide plus dexamethasone) is effective in the treatment of MM 61 , no randomized trial has compared the efficacy and safety of lenalidomide-based versus thalidomide-based viii This is illustrated by idiosyncratic drug-induced liver injury (DILI). DILI is the most common single adverse drug reaction (ADR), which led to its withdrawal from the market 49 . Idiosyncratic DILI is a rare (10 -3 to 10 -4 ) ADR that cannot be predicted by pre-clinical animal studies and is unlikely to be detected in typical phase-III clinical trials (involving 10 2 to 10 3 patients). ix All three thiazolidinediones are oral hypoglycemic agents, agonists of PPAR- (peroxisome proliferator-activated receptor gamma) and possess antiinfl ammatory properties. After a lengthy debate, rosiglitazone was removed from the market in many countries owing to post-marketing evidence that it increases the risk of myocardial infarct 50 . Recent post-marketing studies also provided evidence that pioglitazone and rosiglitazone enhanced the risk of bladder cancer in diabetic patients who used these drugs for one or more years 51 .
x The viewpoint of the Brazilian agency of health surveillance, ANVISA, on "me too" drugs was, to some extent, based on its advisory technical committee on medicines (CATEME) report. xi The mechanism of the teratogenic action of thalidomide and its remarkable species-specifi city remained a complete mystery for nearly fi ve decades. Recently, a study by Ito et al. 57, 58 has started to decipher this enigma. Ito et al. identifi ed cereblon (encoded by the CRBN gene) as a thalidomide-binding protein. Thalidomide binding to CRBN and inhibiting the associated ubiquitin ligase activity is the fi rst step in a chain of events that leads to limb malformations in chicks, fi sh (fi ns), rabbits and primates but not in rats and mice. Along this line, recent studies have suggested that CRBN expression is required for antimyeloma activity of lenalidomide, pomalidomide and thalidomide 59 . Therefore, it is possible that, mechanistically, teratogenicity and the antimyeloma activity of thalidomide analogues are two sides of the same coin. regimens. A retrospective ("case-control") study by Gay et al. 64 compared the effi cacy and toxicity of lenalidomide plus dexamethasone (len/dex) versus thalidomide plus dexamethasone (tha/dex) as initial therapy for newly diagnosed MM, and suggested that the former regimen would be somewhat more effec- the most common AEs among tha/dex-patients were venous thromboembolism (15.3% vs 9.2%, P = 0.058) and peripheral neuropathy (10.4% vs 0.9%, P < 0.001 65 . An increased number of secondary primary malignancies have also been reported in several studies using lenalidomide maintenance 65 .
In July 2010, ANVISA rejected a new drug application for lenalidomide use in MM and myelodysplastic syndromes 66 . On that occasion, the advisory technical committee on medicines ("CATEME") had recommended the agency not to approve lenalidomide for marketing, as no evidence (from sound comparative clinical trials) was presented to show that it was clinically superior to thalidomide-based regimens adopted in the treatment of MM and myelodysplastic syndrome 66 . The company fi led a reconsideration request in July 2010, and in December 2012 ANVISA confi rmed its previous decision to deny lenalidomide registration in the country 66 .
In summary, so far unequivocal evidence is lacking to support any claim that thalidomide analogues are more effective than their prototype drug (thalidomide) for MM or any other clinical indication. and concern has grown over the rising costs of treatments. The cost-effectiveness of MM treatment regimens, for instance, has i.e., in the USA thalidomide is 122 times more expensive than in Brazil. For the Brazilian public health system (SUS), therefore, the difference between the costs of thalidomide-and lenalidomide-based treatment regimens for MM and other chronic diseases is tremendous.
Conclusion
As previously mentioned, the law (No. 10.651/2003) prohibits sales and imposes restrictions on the dispensing and distribution of thalidomide but makes no provision for its teratogenic analogues. Notwithstanding the fact that lenalidomide has recently received a denial approval decision, sooner or later ANVISA will approve the marketing of novel thalidomide analogues. If the thalidomide law remains unchanged, a worrying scenario can be foreseen. Current law does not prohibit the sale and dispensing of thalidomide (teratogenic) analogues in commercial pharmacies. Moreover, new product promotion by companies is likely to increase the frequency with which analogues are prescribed, regardless of their cost-effectiveness.
For the sake of coherent drug regulation, the current law must be amended so that restrictions on thalidomide sales, distribution and dispensing are extended to those analogues that are proven or suspected to be human teratogens. Additionally, xii Gay et al.'s investigation 64 was a "case-control" designed study based on the Mayo Clinic's (USA) medical records. a clause should be included stating that thalidomide analogues can only be registered in the country if gold-standard xiii comparative clinical trials demonstrate that they are clinically superior (in terms of effi cacy and/or safety) to thalidomide-based (optimized) therapeutic regimens. The foregoing legal provision is needed to strengthen regulatory decisions that make exceptions to ANVISA's rule of not rejecting approvals for marketing based merely on the fact that the drugs are putative "me-too"s (e.g., lenalidomide). It is of note that the "me-too" supporters' argument -that imitation medicines stimulate competition, thereby contributing to a reduction in drug prices -does not hold true for thalidomide and its analogues. In this particular case, the costs of treatment regimens are, in one way or another, covered predominantly by the public health system. It seems fair, therefore, that cost-effectiveness should be a requisite for the registration of novel thalidomide analogues.
In conclusion, restrictions imposed by current law on the sale and dispensing of thalidomide must be extended to its teratogenic analogues, otherwise a door is open to approve costly "me-too" drugs that are not clinically superior to their prototype medicine. Needless to say, the costs of expensive thalidomide "me-too" drugs are likely to be met predominantly, if not entirely, by the public health system.
